Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn

Table of Contents

January 01, 2006; Volume 34,Issue 1

MINIREVIEWS

  • You have access
    MECHANISM-BASED INACTIVATION AND REVERSIBILITY: IS THERE A NEW TREND IN THE INACTIVATION OF CYTOCHROME P450 ENZYMES?
    Anna L. Blobaum
    Drug Metabolism and Disposition January 2006, 34 (1) 1-7; DOI: https://doi.org/10.1124/dmd.105.004747

Short Communications

  • You have access
    DOSE-DEPENDENT LEVELS OF EPIGALLOCATECHIN-3-GALLATE IN HUMAN COLON CANCER CELLS AND MOUSE PLASMA AND TISSUES
    Joshua D. Lambert, Mao-Jung Lee, Lauren Diamond, Jihyeung Ju, Jungil Hong, Mousumi Bose, Harold L. Newmark and Chung S. Yang
    Drug Metabolism and Disposition January 2006, 34 (1) 8-11; DOI: https://doi.org/10.1124/dmd.104.003434
  • You have access
    FUNCTIONAL CHARACTERIZATION AND HAPLOTYPE ANALYSIS OF POLYMORPHISMS IN THE HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER, ENT2
    Ryan P. Owen, Leah L. Lagpacan, Travis R. Taylor, Melanie De La Cruz, Conrad C. Huang, Michiko Kawamoto, Susan J. Johns, Doug Stryke, Thomas E. Ferrin and Kathleen M. Giacomini
    Drug Metabolism and Disposition January 2006, 34 (1) 12-15; DOI: https://doi.org/10.1124/dmd.105.006270
  • You have access
    ROLE OF HUMAN CYCLOOXYGENASE-2 IN THE BIOACTIVATION OF DAPSONE AND SULFAMETHOXAZOLE
    Piyush M. Vyas, Sanjoy Roychowdhury and Craig K. Svensson
    Drug Metabolism and Disposition January 2006, 34 (1) 16-18; DOI: https://doi.org/10.1124/dmd.105.006890

Articles

  • You have access
    QUANTITATIVE ANALYSIS OF FMO GENE mRNA LEVELS IN HUMAN TISSUES
    Jun Zhang and John R. Cashman
    Drug Metabolism and Disposition January 2006, 34 (1) 19-26; DOI: https://doi.org/10.1124/dmd.105.006171
  • You have access
    MODULATION OF CYP1A2 AND CYP3A6 CATALYTIC ACTIVITIES BY SERUM FROM RABBITS WITH A TURPENTINE-INDUCED INFLAMMATORY REACTION AND INTERLEUKIN 6
    Oksana Kourylko, Caroline Fradette, Mathieu Arcand and Patrick du Souich
    Drug Metabolism and Disposition January 2006, 34 (1) 27-35; DOI: https://doi.org/10.1124/dmd.105.006528
  • You have access
    INHIBITION AND RECOVERY OF RAT HEPATIC GLUTATHIONE S-TRANSFERASE ZETA AND ALTERATION OF TYROSINE METABOLISM FOLLOWING DICHLOROACETATE EXPOSURE AND WITHDRAWAL
    Xu Guo, Vaishali Dixit, Huiping Liu, Albert L. Shroads, George N. Henderson, Margaret O. James and Peter W. Stacpoole
    Drug Metabolism and Disposition January 2006, 34 (1) 36-42; DOI: https://doi.org/10.1124/dmd.105.003996
  • You have access
    DETERMINATION OF THE ENZYME(S) INVOLVED IN THE METABOLISM OF AMIODARONE IN LIVER AND INTESTINE OF RAT: THE CONTRIBUTION OF CYTOCHROME P450 3A ISOFORMS
    Anooshirvan Shayeganpour, Ayman O. S. El-Kadi and Dion R. Brocks
    Drug Metabolism and Disposition January 2006, 34 (1) 43-50; DOI: https://doi.org/10.1124/dmd.105.006742
  • You have access
    STRUCTURAL ELUCIDATION OF HYDROXYLATED METABOLITES OF THE ISOFLAVAN EQUOL BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
    Corinna E. Rüfer, Hansruedi Glatt and Sabine E. Kulling
    Drug Metabolism and Disposition January 2006, 34 (1) 51-60; DOI: https://doi.org/10.1124/dmd.105.004929
  • You have access
    CYP2A5-MEDIATED ACTIVATION AND EARLY ULTRASTRUCTURAL CHANGES IN THE OLFACTORY MUCOSA: STUDIES ON 2,6-DICHLOROPHENYL METHYLSULFONE
    Anna Franzén, Carina Carlsson, Veronica Hermansson, Matti Lang and Eva B. Brittebo
    Drug Metabolism and Disposition January 2006, 34 (1) 61-68; DOI: https://doi.org/10.1124/dmd.105.006221
  • You have access
    EFFECT OF MILK THISTLE (SILYBUM MARIANUM) AND BLACK COHOSH (CIMICIFUGA RACEMOSA) SUPPLEMENTATION ON DIGOXIN PHARMACOKINETICS IN HUMANS
    Bill J. Gurley, Gary W. Barone, D. Keith Williams, Julie Carrier, Philip Breen, C. Ryan Yates, Peng-fei Song, Martha A. Hubbard, Yudong Tong and Sreekhar Cheboyina
    Drug Metabolism and Disposition January 2006, 34 (1) 69-74; DOI: https://doi.org/10.1124/dmd.105.006312
  • You have access
    EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS
    Caroline Aninat, Amélie Piton, Denise Glaise, Typhen Le Charpentier, Sophie Langouët, Fabrice Morel, Christiane Guguen-Guillouzo and André Guillouzo
    Drug Metabolism and Disposition January 2006, 34 (1) 75-83; DOI: https://doi.org/10.1124/dmd.105.006759
  • You have access
    APPLICATION OF A GENERIC PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO THE ESTIMATION OF XENOBIOTIC LEVELS IN RAT PLASMA
    F. A. Brightman, D. E. Leahy, G. E. Searle and S. Thomas
    Drug Metabolism and Disposition January 2006, 34 (1) 84-93; DOI: https://doi.org/10.1124/dmd.105.004804
  • You have access
    APPLICATION OF A GENERIC PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO THE ESTIMATION OF XENOBIOTIC LEVELS IN HUMAN PLASMA
    F. A. Brightman, D. E. Leahy, G. E. Searle and S. Thomas
    Drug Metabolism and Disposition January 2006, 34 (1) 94-101; DOI: https://doi.org/10.1124/dmd.105.004838
  • You have access
    ACYL-COENZYME A FORMATION OF SIMVASTATIN IN MOUSE LIVER PREPARATIONS
    Chunze Li, Raju Subramanian, Sean Yu and Thomayant Prueksaritanont
    Drug Metabolism and Disposition January 2006, 34 (1) 102-110; DOI: https://doi.org/10.1124/dmd.105.006650
  • You have access
    NC100668, A NEW TRACER FOR IMAGING OF VENOUS THROMBOEMBOLISM: DISPOSITION AND METABOLISM IN RATS
    Tore Skotland, Svein Olaf Hustvedt, Inger Oulie, Petter Balke Jacobsen, Grete Arneberg Friisk, Ann Svendsen Langøy, Steinar Uran, Jessie Sandosham, Alan Cuthbertson and Kim Gunnar Toft
    Drug Metabolism and Disposition January 2006, 34 (1) 111-120; DOI: https://doi.org/10.1124/dmd.105.006239
  • You have access
    METABOLISM AND DISPOSITION OF VARENICLINE, A SELECTIVE α4β2 ACETYLCHOLINE RECEPTOR PARTIAL AGONIST, IN VIVO AND IN VITRO
    R. Scott Obach, Anne E. Reed-Hagen, Suzanne S. Krueger, Beth J. Obach, Thomas N. O'Connell, Kathleen S. Zandi, Sandra Miller and Jotham W. Coe
    Drug Metabolism and Disposition January 2006, 34 (1) 121-130; DOI: https://doi.org/10.1124/dmd.105.006767
  • You have access
    NUCLEAR RECEPTOR EXPRESSION IN FETAL AND PEDIATRIC LIVER: CORRELATION WITH CYP3A EXPRESSION
    Carrie A. Vyhlidal, Roger Gaedigk and J. Steven Leeder
    Drug Metabolism and Disposition January 2006, 34 (1) 131-137; DOI: https://doi.org/10.1124/dmd.105.005967
  • You have access
    TRANSCRIPTIONAL REGULATION OF THE PXR GENE: IDENTIFICATION AND CHARACTERIZATION OF A FUNCTIONAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR α BINDING SITE WITHIN THE PROXIMAL PROMOTER OF PXR
    Sihem Aouabdi, Gordon Gibson and Nick Plant
    Drug Metabolism and Disposition January 2006, 34 (1) 138-144; DOI: https://doi.org/10.1124/dmd.105.006064
  • You have access
    EVIDENCE FOR THE BIOACTIVATION OF ZOMEPIRAC AND TOLMETIN BY AN OXIDATIVE PATHWAY: IDENTIFICATION OF GLUTATHIONE ADDUCTS IN VITRO IN HUMAN LIVER MICROSOMES AND IN VIVO IN RATS
    Qing Chen, George A. Doss, Elaine C. Tung, Wensheng Liu, Yui S. Tang, Matthew P. Braun, Varsha Didolkar, John R. Strauss, Regina W. Wang, Ralph A. Stearns, David C. Evans, Thomas A. Baillie and Wei Tang
    Drug Metabolism and Disposition January 2006, 34 (1) 145-151; DOI: https://doi.org/10.1124/dmd.105.004341
  • You have access
    TRANSCRIPTIONAL REGULATION OF THE NAD(P)H:QUINONE OXIDOREDUCTASE 1 AND GLUTATHIONE S-TRANSFERASE YA GENES BY MERCURY, LEAD, AND COPPER
    Hesham M. Korashy and Ayman O. S. El-Kadi
    Drug Metabolism and Disposition January 2006, 34 (1) 152-165; DOI: https://doi.org/10.1124/dmd.105.005397
  • You have access
    PREDICTION OF TIME-DEPENDENT CYP3A4 DRUG-DRUG INTERACTIONS: IMPACT OF ENZYME DEGRADATION, PARALLEL ELIMINATION PATHWAYS, AND INTESTINAL INHIBITION
    Aleksandra Galetin, Howard Burt, Laura Gibbons and J. Brian Houston
    Drug Metabolism and Disposition January 2006, 34 (1) 166-175; DOI: https://doi.org/10.1124/dmd.105.006874
  • You have access
    IN VITRO METABOLISM OF NAPHTHALENE BY HUMAN LIVER MICROSOMAL CYTOCHROME P450 ENZYMES
    Taehyeon M. Cho, Randy L. Rose and Ernest Hodgson
    Drug Metabolism and Disposition January 2006, 34 (1) 176-183; DOI: https://doi.org/10.1124/dmd.105.005785
  • You have access
    SLOW ELIMINATION OF NONYLPHENOL FROM RAT INTESTINE
    Tomo Daidoji, Mihoko Ozawa, Hirokazu Sakamoto, Toshiro Sako, Hiroki Inoue, Ryo Kurihara, Shinya Hashimoto and Hiroshi Yokota
    Drug Metabolism and Disposition January 2006, 34 (1) 184-190; DOI: https://doi.org/10.1124/dmd.105.007229

Accelerated Communication

  • You have access
    GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS
    Brian W. Ogilvie, Donglu Zhang, Wenying Li, A. David Rodrigues, Amy E. Gipson, Jeff Holsapple, Paul Toren and Andrew Parkinson
    Drug Metabolism and Disposition January 2006, 34 (1) 191-197; DOI: https://doi.org/10.1124/dmd.105.007633
Back to top
PreviousNext

In this issue

Drug Metabolism and Disposition: 34 (1)
Drug Metabolism and Disposition
Vol. 34, Issue 1
1 Jan 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts

Jump to

  • MINIREVIEWS
  • Short Communications
  • Articles
  • Accelerated Communication
  • Most Cited
  • Most Read
Loading
  • Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
  • Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes
  • DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
  • In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model
  • THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics